ArticleAsian journal of andrology2011
Fluoroquinolone-macrolide combination therapy for chronic bacterial prostatitis: retrospective analysis of pathogen eradication rates, inflammatory findings and sexual dysfunction.
Article in Asian journal of andrology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Management of premature ejaculation: a clinical guideline from the Italian Society of Andrology and Sexual Medicine (SIAMS).Journal of endocrinological investigation · 2021Guideline
- Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline.BJU international · 2015Guideline
- Antibiotic Pharmacokinetics and Prostate Penetration in Bacterial Prostatitis: A Systematic Review.Infectious diseases and therapy · 2026Review
- Prostatitis-Related Male Infertility: From Inflammation and Dysbiosis to Sperm DNA Damage.Diagnostics (Basel, Switzerland) · 2026Review
- Current Understanding of Androgen Signaling in Prostatitis and its Treatment: A Review.Current medicinal chemistry · 2024Review
- Pre- and post-LEEP: analysis of the female urogenital tract microenvironment and its association with sexual dysfunction.Sexual medicine · 2023Article
- Chitosan-Coated Azithromycin/Ciprofloxacin-Loaded Polycaprolactone Nanoparticles: A Characterization and Potency Study.Nanotechnology, science and applications · 2023Article
- Effect of lactoferrin on murine sperm apoptosis induced by intraperitoneal injection of lipopolysaccharide.The Journal of veterinary medical science · 2021Article
- Effect of lactoferrin on murine embryo development created from lipopolysaccharide-treated sperm.The Journal of veterinary medical science · 2021Article
- Spectrum of Causative Pathogens and Resistance Rates to Antibacterial Agents in Bacterial Prostatitis.Diagnostics (Basel, Switzerland) · 2021Article
- Assessment of the in vitro activity of azithromycin niosomes alone and in combination with levofloxacin on extensively drug-resistant Klebsiella pneumoniae clinical isolates.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2021Article
- Management of Chronic Bacterial Prostatitis.Current urology reports · 2020Review
- Pharmacological Interventions for Bacterial Prostatitis.Frontiers in pharmacology · 2020Review
- Mounting resistance of uropathogens to antimicrobial agents: A retrospective study in patients with chronic bacterial prostatitis relapse.Investigative and clinical urology · 2017Article
- Conservative Nonhormonal Options for the Treatment of Male Infertility: Antibiotics, Anti-Inflammatory Drugs, and Antioxidants.BioMed research international · 2017Review
- Aminoglycoside antibiotics for NIH category II chronic bacterial prostatitis: A single-cohort study with one-year follow-up.Experimental and therapeutic medicine · 2016Article
- Chronic prostatitis/chronic pelvic pain syndrome: a review of evaluation and therapy.Prostate cancer and prostatic diseases · 2016Review
- Multimodal therapy for category III chronic prostatitis/chronic pelvic pain syndrome in UPOINTS phenotyped patients.Experimental and therapeutic medicine · 2015Article
- A systematic review of the correlates and management of nonpremature ejaculatory dysfunction in heterosexual men.Therapeutic advances in urology · 2013Article
- Bacterial prostatitis.World journal of urology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We previously demonstrated the safety and efficacy of fluoroquinolone-macrolide combination therapy in category II chronic bacterial prostatitis (CBP). The aim of this study is to retrospectively compare the microbiological and clinical findings of two treatment schemes for CBP based on the combination of azithromycin (500 mg, thrice-weekly) with a once-daily 500- or 750-mg dose of ciprofloxacin (Cipro-500 or Cipro-750 cohort, respectively). Combined administration of azithromycin (1500 mg week(-1)) with ciprofloxacin at the rate of 750 mg day(-1) for 4 weeks rather than at 500 mg day(-1) for 6 weeks increased the eradication rates from 62.35% to 77.32% and the total bacteriological success from 71.76% to 85.57%. A significant decrease in pain and voiding signs/symptoms and a significant reduction in inflammatory leukocyte counts and serum prostate-specific antigen (PSA) were sustained throughout an 18-month follow-up period in both groups. Ejaculatory pain, haemospermia and premature ejaculation were significantly attenuated on microbiological eradication in both groups, but the latter subsided more promptly in the Cipro-750 cohort. In total, 59 Cipro-750 patients showed mild-to-severe erectile dysfunction (ED) at baseline, while 22 patients had no ED on microbiological eradication and throughout the follow-up period. In conclusion fluoroquinolone-macrolide therapy resulted in pathogen eradication and CBP symptom attenuation, including pain, voiding disturbances and sexual dysfunction. A once-daily 750-mg dose of ciprofloxacin for 4 weeks showed enhanced eradication rates and lower inflammatory white blood cell counts compared to the 500-mg dose for 6 weeks. Our results are open to further prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.